LinkedIn CPL
$400-$800
Pharma/biotech targets
Avg. Sales Cycle
9-18 mo
Enterprise deals
Avg. Deal Size
$100K+
Annual contracts
Why Life Sciences Has Higher CPLs
Life sciences and pharma represent some of the most specialized B2B audiences. Scientists, regulatory professionals, and R&D leaders are a small, highly targeted group. The niche nature of these audiences drives up CPLs, but the high deal values justify the investment.
Key insight: Compliance and validation messaging resonates strongly. Life sciences buyers prioritize regulatory compliance (FDA, GxP) over features. Lead with certifications and audit trails.
Benchmarks by Audience
| Audience | CPL Range | Notes |
|---|---|---|
| R&D / Scientists | Content-heavy approach | |
| Regulatory / QA | Compliance-focused messaging | |
| VP/Director Level | Executive targeting |
42 Agency Insight: Life sciences buyers trust peer validation over vendor claims. Peer-reviewed case studies, conference presence, and scientific advisory board endorsements drive significantly higher conversion rates than traditional marketing content.
Recommended Targeting
| Audience | Job Titles | Industries |
|---|---|---|
| Research & Development | VP R&D, Director Research, Principal Scientist | Biotech, Pharma |
| Quality & Regulatory | VP Quality, Director Regulatory Affairs, QA Manager | Pharma, Medical Devices |
| Clinical Operations | Director Clinical Ops, Clinical Trial Manager | CROs, Pharma |
Get the Life Sciences Playbook
Complete targeting specs and compliance-focused messaging strategies.